Full history for every metric is available with a Kvantra account
Iterum Therapeutics plc (ITRM)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -19 | -20 | |||||
| Net profit | $m | -103 | -52 | -92 | -44 | -38 | -25 | -27 |
| EPS reported | $ | -1.26 | -0.75 | |||||
| Operating cashflow per share | $ | -1.36 | -0.34 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.36 | -0.34 | |||||
| Free cash flow | $m | -27 | -20 | |||||
| Net debt | $m | 21 | 23 | |||||
| Book value equity | $m | -4 | -7 | |||||
| Book value per share | $ | -0.21 | -0.16 | |||||
| Number of shares | m | 19.7 | 45.8 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -8.54 | -0.22 | |||||
| P/S LTM | x | 0.00 | 4.10 | |||||
| P/FCF LTM | x | -1.30 | -0.08 | |||||
| EV/EBITDA LTM | x | -2.59 | -1.05 | |||||
| EV/Sales LTM | x | 0.00 | 62.39 | |||||
| Earnings Yield LTM | % | -71.05% | -1483.1% | |||||
| FCF Yield | % | -76.78% | -1246.5% | |||||
| Quality | ||||||||
| ROE | % | 607.06% | 442.32% | |||||
| ROIC | % | -45.10% | -63.07% | |||||
| Operating margin | % | 0.00% | -4261.8% | |||||
| Gross margin | % | 0.00% | -171.28% | |||||
| FCF/Sales | % | - | -4018.8% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.59 | -0.59 | |||||
| Net Debt/EBITDA | x | -0.99 | -1.29 | |||||
| EBIT/Net interest | x | -7.41 | -11.67 | |||||
| Net debt/market cap | % | 61.40% | 1421.9% | |||||
| Net debt/Equity | x | -5.25 | -3.08 | |||||
| Gross debt/equity | x | -11.16 | -4.57 | |||||
Company overview
Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc is a clinical-stage biopharmaceutical firm dedicated to the development and commercialization of anti-infective treatments. The company operates across Ireland, Bermuda, and the United States. Its primary therapeutic candidate is sulopenem, an innovative antimicrobial compound available in both oral and intravenous formulations. Sulopenem is currently undergoing advanced (Phase III) clinical evaluation for its potential in addressing uncomplicated and complicated urinary tract infections, as well as complicated intra-abdominal infections. Established in 2015, Iterum Therapeutics maintains its corporate headquarters in Dublin, Ireland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free